NYSE:AORTMedical Equipment
Assessing Artivion (AORT) Valuation After Positive Analyst Views On Aortic Pipeline And NEXUS Trial Results
Recent analyst reports on Artivion (AORT) have zeroed in on the company’s aortic disease pipeline, with particular attention on the NEXUS stent graft system and its one year trial results, which show strong sealing and low complication rates.
See our latest analysis for Artivion.
Artivion’s share price has eased back recently, with a 30 day share price return of 8.23% and a 90 day share price return of 20.07% from a last close of US$36.35. However, the 1 year total shareholder return of...